olmesartan medoxomil + placebo + olmesartan medoxomil + olmesartan medoxomil
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Metabolic Syndrome
Conditions
Metabolic Syndrome, Hypertension
Trial Timeline
Aug 1, 2008 → May 1, 2011
NCT ID
NCT00676845About olmesartan medoxomil + placebo + olmesartan medoxomil + olmesartan medoxomil
olmesartan medoxomil + placebo + olmesartan medoxomil + olmesartan medoxomil is a phase 3 stage product being developed by Daiichi Sankyo for Metabolic Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00676845. Target conditions include Metabolic Syndrome, Hypertension.
What happened to similar drugs?
19 of 20 similar drugs in Metabolic Syndrome were approved
Approved (19) Terminated (4) Active (1)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00676845 | Phase 3 | Completed |
Competing Products
20 competing products in Metabolic Syndrome